# The Efficacy of a Combination of Telmisartan/S-Amlodipine Compared With Telmisartan Monotherapy

Study · id `cardio:ct-nct02231788` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT02231788](<https://clinicaltrials.gov/study/NCT02231788>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT02231788

Browse, organ or system: Blood vessels  
Browse, condition area: High blood pressure  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 217 participants.

## Technical summary

Registry record NCT02231788. Randomized; no masking; primary purpose treatment. Start 2014-06 (actual); primary completion 2018-03 (actual). Results not posted.

## Key facts

- Design: Interventional study; randomized; no masking; primary purpose treatment
- Phase: Phase 4
- Enrolled: 217 participants (enrolled count; ClinicalTrials.gov record NCT02231788, source copy `cardio:ctgov-nct02231788-2020-01-31`, retrieved 2026-10-26)
- Started: 2014-06 (actual) (ClinicalTrials.gov record NCT02231788, source copy `cardio:ctgov-nct02231788-2020-01-31`, retrieved 2026-10-26)
- Primary completion: 2018-03 (actual) (ClinicalTrials.gov record NCT02231788, source copy `cardio:ctgov-nct02231788-2020-01-31`, retrieved 2026-10-26)
- Completion: 2018-03 (actual) (ClinicalTrials.gov record NCT02231788, source copy `cardio:ctgov-nct02231788-2020-01-31`, retrieved 2026-10-26)
- Countries: South Korea (ClinicalTrials.gov record NCT02231788, source copy `cardio:ctgov-nct02231788-2020-01-31`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct02231788-2020-01-31`, retrieved 2026-10-26)

## The registry's words

- Brief title: The Efficacy of a Combination of Telmisartan/S-Amlodipine Compared With Telmisartan Monotherapy
- Acronym: TENUVA-BP
- Condition: Hypertension
- Intervention (Drug): Telminuvo®Tab. 40/2.5mg
- Intervention (Drug): Telmitrend®Tab. 80mg
- Lead sponsor: Chong Kun Dang Pharmaceutical
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Hypertension (high blood pressure) (`core:hypertension`)
- Registry lists this organization as the lead sponsor: Chong Kun Dang Pharmaceutical (`cardio:org-chong-kun-dang-pharmaceutical`)

## Provenance

Content hash: 81f43bc92e90683e0be71c80203dd7ab3036d897707b49721c604d294125add3
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
